Wayne Koberstein

  1. Coming Out Of Stealth Mode: What To Know And Do 8/2/2021

    In Part two of this two-part series, we look at what companies should do to make the exit from stealth mode an effective exchange with the outside world — how to identify and reach investors, influencers, and stakeholders in a company’s pursuit of new treatments for diseases, from rare conditions to widespread medical challenges, some at the scale of public health.

  2. Companies To Watch: AMO Pharma 8/2/2021

    AMO Pharma is applying “de-risked” compounds as potential medicines for rare diseases in brain development.

  3. Companies To Watch: NervGen Pharma 7/1/2021

    NervGen Pharma is going beyond preclinicals to human trials for a drug that could repair and regrow neurons.

  4. The Collective Benefits Of A Collaborative CFO 7/1/2021

    Terry Coelho, CFO, works as a team member, not just a finance manager, at BioDelivery Sciences.

  5. Coming Out Of Stealth Mode: What To Know And Do 7/1/2021

    Five CEOs discuss their experiences with stealth mode transitions. They address when and how a company should turn away from that introspective state and show itself to the world.

  6. Companies To Watch: IM Therapeutics 6/1/2021

    Our company to watch this month is IM Therapeutics, which focuses on developing small molecule therapies for Type 1 diabetes, celiac disease, and other autoimmune conditions.

  7. Synergistic COVID Therapy Development 5/3/2021

    From the outside, it may look as if Biophytis took a sharp turn from its focus on aging to address Covid. But look again.

  8. Companies To Watch: Lyra Therapeutics 5/3/2021

    Our company to watch this month, Lyra Therapeutics, is focused on controlling chronic ENT conditions with precise drug elution and long action.

  9. 180 Life Sciences: Deliberately Seeking Serendipity 4/1/2021

    At 180 Life Sciences, veterans of the old-pharma world are building a small bio enterprise focused evenly on scientific and market opportunities in the inflammation space.

  10. Companies To Watch: Carisma Therapeutics 4/1/2021

    Carisma Therapeutics is a private company developing CAR-M (chimeric antigen receptor macrophage) as an alternative to CAR-T (CAR-T cell) and potential treatment for solid tumors rather than just liquid cancers.